Tags

Type your tag names separated by a space and hit enter

The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.
Am J Gastroenterol. 1997 Feb; 92(2):212-5.AJ

Abstract

OBJECTIVES

Barrett's esophagus is a premalignant condition defined by the presence of intestinal metaplasia in the esophagus. Estimates of the incidence of adenocarcinoma developing in patients with Barrett's esophagus vary widely. We prospectively followed a cohort of patients to define the incidence.

METHODS

Between January 1982 and April 1995, all patients undergoing upper endoscopy at the VA Medical Center in Tucson, AZ, were surveyed for Barrett's esophagus. One hundred seventy-seven patients (174 males, three females) were found to have Barrett's esophagus. Seven of 177 were found to have adenocarcinoma either at initial endoscopy or within 6 months, resulting in a prevalence of 4%. One hundred seventy of 177 patients initially lacking cancer were available for systematic survey.

RESULTS

The mean age at the time of Barrett's diagnosis was 62 yr (range 30-85 yr). The mean follow-up period was 57 months or 4.8 yr (range 6-156 months), for a total of 834 patient-years. Adenocarcinoma developed in four patients, an incidence of 1/208 patient-years of follow-up.

CONCLUSIONS

The current series is larger and has a longer follow-up period than previous prospective trials and demonstrates a lower incidence of adenocarcinoma. Surveillance of patients with Barrett's esophagus for dysplasia remains an appropriate clinical practice.

Authors+Show Affiliations

Section of Gastroenterology, Veterans Affairs Medical Center, Tucson, Arizona 85723, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9040193

Citation

Drewitz, D J., et al. "The Incidence of Adenocarcinoma in Barrett's Esophagus: a Prospective Study of 170 Patients Followed 4.8 Years." The American Journal of Gastroenterology, vol. 92, no. 2, 1997, pp. 212-5.
Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92(2):212-5.
Drewitz, D. J., Sampliner, R. E., & Garewal, H. S. (1997). The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. The American Journal of Gastroenterology, 92(2), 212-5.
Drewitz DJ, Sampliner RE, Garewal HS. The Incidence of Adenocarcinoma in Barrett's Esophagus: a Prospective Study of 170 Patients Followed 4.8 Years. Am J Gastroenterol. 1997;92(2):212-5. PubMed PMID: 9040193.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. AU - Drewitz,D J, AU - Sampliner,R E, AU - Garewal,H S, PY - 1997/2/1/pubmed PY - 1997/2/1/medline PY - 1997/2/1/entrez SP - 212 EP - 5 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 92 IS - 2 N2 - OBJECTIVES: Barrett's esophagus is a premalignant condition defined by the presence of intestinal metaplasia in the esophagus. Estimates of the incidence of adenocarcinoma developing in patients with Barrett's esophagus vary widely. We prospectively followed a cohort of patients to define the incidence. METHODS: Between January 1982 and April 1995, all patients undergoing upper endoscopy at the VA Medical Center in Tucson, AZ, were surveyed for Barrett's esophagus. One hundred seventy-seven patients (174 males, three females) were found to have Barrett's esophagus. Seven of 177 were found to have adenocarcinoma either at initial endoscopy or within 6 months, resulting in a prevalence of 4%. One hundred seventy of 177 patients initially lacking cancer were available for systematic survey. RESULTS: The mean age at the time of Barrett's diagnosis was 62 yr (range 30-85 yr). The mean follow-up period was 57 months or 4.8 yr (range 6-156 months), for a total of 834 patient-years. Adenocarcinoma developed in four patients, an incidence of 1/208 patient-years of follow-up. CONCLUSIONS: The current series is larger and has a longer follow-up period than previous prospective trials and demonstrates a lower incidence of adenocarcinoma. Surveillance of patients with Barrett's esophagus for dysplasia remains an appropriate clinical practice. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/9040193/The_incidence_of_adenocarcinoma_in_Barrett's_esophagus:_a_prospective_study_of_170_patients_followed_4_8_years_ L2 - https://ClinicalTrials.gov/search/term=9040193 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -